Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine.

Abstract

Nine patients with lamivudine-resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high-dose adefovir (20 mg/day). The response to the increased dose of adefovir was compared with the response in 15 patients with a suboptimal response who did not receive an increase in the dose of adefovir. The increase in the dose of adefovir did not lead to a significant reduction in hepatitis B DNA when compared with patients maintained on the standard dose. These data suggest that increasing the dose of adefovir in patients with a suboptimal response does not lead to an improved response.

• Authors: M Viganò, P Lampertico, F Facchetti, G Lunghi, M Colombo
• Journal: Journal of viral hepatitis (J Viral Hepat) Vol. 15 Issue 12 Pg. 922-4 (Dec 2008) ISSN: 1365-2893 [Electronic] England
• PMID: 19087228 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Organophosphonates
• Lamivudine
• adefovir
• Adenine

Topics

• Adenine (administration & dosage, analogs & derivatives)
• Antiviral Agents (administration & dosage)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Drug Resistance, Viral
• Drug Therapy, Combination
• Hepatitis B virus (drug effects)
• Hepatitis B, Chronic (drug therapy)
• Humans
• Lamivudine (administration & dosage)
• Organophosphonates (administration & dosage)
• Treatment Outcome